Here we engineered transgenic Leishmania infantum that express luciferase, the objectives being to more easily monitor in real time their establishment either in BALB/c mice—the liver and spleen being mainly studied—or in vitro. Whatever stationary phase L. infantum promastigotes population—wild type or engineered to express luciferase—the parasite burden was similar in the liver and the spleen at day 30 post the intravenous inoculation of BALB/c mice. Imaging of L. infantum hosting BALB/C mice provided sensitivity in the range of 20,000 to 40,000 amastigotes/mg tissue, two tissues—liver and spleen—being monitored. Once sampled and processed ex vivo for their luciferin-dependent bioluminescence the threshold sensitivity was shown to range from 1,000 to 6,000 amastigotes/mg tissue. This model further proved to be valuable for in vivo measurement of the efficiency of drugs such as miltefosine and may, therefore, additionally be used to evaluate vaccine-induced protection.
Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M (2001) DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 45: 1168–1173. doi: 10.1128/AAC.45.4.1168-1173.2001
[3]
Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 56: 3–7. doi: 10.1016/j.parint.2006.09.001
[4]
Chan MM, Bulinski JC, Chang KP, Fong D (2003) A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein. Parasitol Res 89: 266–271. doi: 10.1007/s00436-002-0706-4
[5]
Kamau SW, Grimm F, Hehl AB (2001) Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro. Antimicrob Agents Chemother 45: 3654–3656. doi: 10.1128/AAC.45.12.3654-3656.2001
[6]
Shimony O, Jaffe CL (2008) Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 75: 196–200. doi: 10.1016/j.mimet.2008.05.026
[7]
Dube A, Gupta R, Singh N (2009) Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 25: 432–439. doi: 10.1016/j.pt.2009.06.006
[8]
Lang T, Goyard S, Lebastard M, Milon G (2005) Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 7: 383–392. doi: 10.1111/j.1462-5822.2004.00468.x
[9]
Mehta SR, Huang R, Yang M, Zhang XQ, Kolli B, et al. (2008) Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery. Clin Vaccine Immunol 15: 1764–1770. doi: 10.1128/CVI.00270-08
[10]
Thalhofer CJ, Graff JW, Love-Homan L, Hickerson SM, Craft N, et al. (2010) In vivo imaging of transgenic Leishmania parasites in a live host. J Vis Exp.
[11]
Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, et al. (2010) Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol. doi: 10.1016/j.exppara.2010.12.006
[12]
de La Llave E, Lecoeur H, Besse A, Milon G, Prina E, et al. (2011) A combined luciferase imaging and reverse transcription polymerase chain reaction assay for the study of Leishmania amastigote burden and correlated mouse tissue transcript fluctuations. Cell Microbiol 13: 81–91. doi: 10.1111/j.1462-5822.2010.01521.x
[13]
Lang T, Lecoeur H, Prina E (2009) Imaging Leishmania development in their host cells. Trends Parasitol 25: 464–473. doi: 10.1016/j.pt.2009.07.006
[14]
Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, et al. (2003) An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol 130: 31–42. doi: 10.1016/S0166-6851(03)00142-7
[15]
Ferrua B, Le Fichoux Y, Suffia I, Rousseau D, Roptin C, et al. (2001) Quantitation of Leishmania infantum in tissues of infected BALB/c mouse by sandwich ELISA. J Immunoassay Immunochem 22: 165–181. doi: 10.1081/IAS-100103227
[16]
Ferrua B, Luci C, Le Fichoux Y, Paul A, Marty P (2006) Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge. Vaccine 24: 589–596. doi: 10.1016/j.vaccine.2005.08.057
[17]
Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, et al. (1998) Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 42: 654–658.
[18]
Moreno D, Plano D, Baquedano Y, Jimenez-Ruiz A, Palop JA, et al. (2011) Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates. Parasitol Res 108: 233–239. doi: 10.1007/s00436-010-2073-x
[19]
Claes F, Vodnala SK, van Reet N, Boucher N, Lunden-Miguel H, et al. (2009) Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness. PLoS Negl Trop Dis 3: e486. doi: 10.1371/journal.pntd.0000486
[20]
Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, et al. (2008) Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 105: 14342–14346. doi: 10.1073/pnas.0804105105
